Context: Short children born small for gestational age (SGA) have below-average bone mineral density (BMD). Growth hormone (GH) treatment improves height and BMD in short SGA children. Longitudinal data on BMD in adults born SGA, after GH cessation (GH-stop), are lacking.
S hort stature persists in ;10% of children born small for gestational age (SGA) (1) . The mechanisms underlying this lack of catch-up growth are largely unknown but could be related to disturbances in the growth hormone (GH)-insulinlike growth factor-1 (IGF-1) axis, which are present in ;60% of short SGA children (2) .
Osteoporosis is a worldwide problem with high morbidity and increased mortality (3, 4) . Bone mineral density (BMD) of the total body (BMD TB ) and bone mineral apparent density of the lumbar spine (BMAD LS ) are important determinants of fracture risk and osteoporosis in later life (5, 6) . BMD TB and BMAD LS increase during childhood, and peak bone mass is normally attained between the ages of 18-20 years in girls and 18-23 years in boys (7) . Bone strength in later life largely depends on this attained peak bone mass (8) .
GH and IGF-1 have a well-recognized role not only in bone elongation and skeletal maturation but also in the regulation of BMD (9) (10) (11) . This could explain why low BMD TB and BMAD LS have been found in children with GH deficiency, idiopathic short stature, and Prader-Willi syndrome (12) (13) (14) . Previous studies have shown that short SGA children have a lower-than-average BMD TB and BMAD LS , even after correction for their short stature (15) (16) (17) .
Short children born SGA can nowadays be treated with GH during childhood to improve adult height (AH). GH treatment also improves BMD TB and BMAD LS on the short term. One study reported an increase of BMD TB from 20.9 to 0.2 standard deviation score (SDS) and an increase of BMAD LS from 20.6 to 0.3 SDS during 3 years of GH treatment (15) . A second study reported an increase of BMAD LS with 0.5 SDS during 6 years of treatment (16) . However, long-term studies on BMD TB and BMAD LS in GH-treated short SGA patients are lacking, and the effects after cessation of treatment are unknown.
In this study, we investigated BMD TB and BMAD LS longitudinally in young adults born SGA who were treated with GH during childhood and had attained an age of 21 years, so that peak bone mass could be evaluated. We hypothesized that BMD TB and BMAD LS had improved during long-term GH treatment and would not be significantly different from 0 SDS at attainment of AH. We also hypothesized that BMD TB and BMAD LS decline in the first months after cessation of GH treatment due to the loss of pharmacologic effects of GH. We compared the data at 5 years after cessation of GH treatment to young adults born SGA with persistent short stature who were never treated with GH, hypothesizing that BMD TB and BMAD LS of GH-treated SGA adults would return to levels of untreated short young adults born SGA. Additionally, we compared the data at 5 years after cessation of GH to those of healthy young adults born appropriate for gestational age (AGA).
Methods

Subjects
The total study group comprised 358 young adults, of whom 173 born SGA had participated in a GH trial (18) (19) (20) . These participants started GH when prepubertal, had a birth length and height below 22.5 SDS, and had no growth failure caused by other disorders. Subjects with a GH deficiency (defined as a serum GH peak response of ,20 mU/L during a GH stimulation test) were excluded. Once daily, 1 mg/m 2 biosynthetic GH (Norditropin; Novo Nordisk A/S, Måløv, Denmark) was given subcutaneously at bedtime. Every 3 months, the GH dose was adjusted to the calculated body surface area.
At attainment of AH (i.e., when height velocity dropped below 0.5 cm in 6 months and bone age was $15 years for girls and $16.5 years for boys), GH treatment was discontinued. Patients were invited to participate in the current longitudinal study evaluating BMD at four time points: at AH (GH-stop) and at 6 months, 2 years, and 5 years after GH cessation. Additionally, data at 5 years after GH cessation were compared with three clinically relevant groups of age-matched healthy young adults (21, 22) 
Measurements
Height was measured to the nearest 0.1 cm (Harpenden stadiometer; Holtain, Pembs, United Kingdom), weight to the nearest 0.1 kg (Servo Balance KA-20-150S; Servo Berkel Prior, Alkmaar, Netherlands). Anthropometric measurements were performed twice according to standardized methods, after which the mean was calculated. Information regarding oral contraceptive use was obtained using questionnaires.
In all participants, BMD TB and BMD of the lumbar spine (BMD LS ), bone mineral content, lean body mass (LBM), and fat mass percentage (FM%) were measured by dual-energy x-ray absorptiometry (Lunar Prodigy; GE Healthcare, Chalfont St. Giles, United Kingdom). BMD TB measurements included the head. All measurements, of both the GH-treated subjects and the control groups, were performed on one machine, and quality assurance was performed daily. All measurements were performed between 2003 and 2016 by the same personnel of the same department. The coefficients of variation were 0.64% for BMD TB and 1.04% for BMD LS (23) .
Serum IGF-1 levels were expressed as SDS adjusted for age and sex, using reference values for healthy children with normal stature, determined in the same laboratory (24) .
Calculations
Height and weight were expressed as SDS adjusted for age and sex according to Dutch reference data (25) and calculated using the Growth Analyser software (http://www.growthanalyser.org).
In all subjects with short stature, true BMD LS is underestimated by the areal presentation and should be corrected for bone size by calculating the BMAD LS (26) . BMAD LS was calculated as follows: BMAD LS = BMD LS 3 [4/(p 3 width)], with the width as the mean width of the second to fourth lumbar vertebral body.
Because BMD TB , BMAD LS , and FM% are dependent on age and sex, SDSs were calculated based on age-and sex-matched reference values from the Dutch population (27, 28) . Because LBM is strongly related to height, LBM was expressed as SDS for height and sex (27) .
Statistical analysis
Distribution of variables was determined by Shapiro-Wilk tests and normal Q-Q plots. Data were compared with 0 using one-sample t tests. Longitudinal changes after cessation of GH treatment were analyzed using repeated measurements analyses with an unstructured covariance type, adjusting for missing data. Multiple linear regression analyses were performed to determine the associations between GH treatment and BMD TB and BMAD LS , with corrections for the possible confounders age, sex, birth weight, height, LBM, FM%, and, in girls, oral contraceptive use. An analysis of covariance was used to compare the four groups, corrected for the confounders identified in the multiple regression analyses.
Results were considered statistically significant if the P value was ,0.05. All analyses were performed with SPSS version 21.0 (SPSS Inc., Chicago, IL). Table 1 shows the clinical characteristics of the 173 GH-treated SGA adults (82 males; 91 females), at start of GH treatment and at AH, when GH treatment was discontinued, and the follow-up study started. Mean [standard deviation (SD)] age at start of GH treatment was 6.2 (2.0) years and height 23.00 (0.6) SDS. After a mean (SD) treatment duration of 10.2 (2.1) years, subjects attained an AH of 21.69 (0.8) SDS.
Results
Clinical characteristics
Longitudinal changes in BMD TB and BMAD LS after GH cessation Figure 1 shows the longitudinal changes in BMD TB and BMAD LS SDS in males and females, until 5 years after GH cessation. At GH cessation, estimated mean [standard error (SE)] BMD TB SDS was 20.40 (0.1) in males and 20.51 (0.1) in females. This was both within the normal range but significantly lower than 0 SDS (P , 0.001). Both males and females had a significantly higher BMD TB at cessation of GH treatment compared with at onset of treatment (P , 0.001 and P = 0.002, respectively). In the 6 months after GH cessation, BMD TB SDS increased significantly in males to 20.30 (0.1) (P = 0.008), followed by a decrease from then onward (P = 0.004). At 5 years after GH cessation, estimated mean (SE) BMD TB SDS was 20.59 (0.1) in males (P = 0.06 compared with BMD TB at GH cessation and P , 0.001 compared with 0 SDS). In females, BMD TB SDS remained stable after cessation of GH treatment: BMD TB SDS was 20.57 (0.1) at 5 years after GH cessation (P = 0.33 compared with BMD TB at GH cessation and P , 0.001 compared with 0 SDS).
At GH cessation, estimated mean (SE) BMAD LS SDS was 20.01 (0.1) in males (P = 0.76 compared with 0 SDS) and 20.29 (0.1) in females (P = 0.003 compared with 0 SDS). Both males and females had a significantly higher BMAD LS at cessation of GH treatment compared with at onset of treatment (P = 0.006 and P = 0.002, respectively). In both males and females, BMAD LS SDS did not change in the 6 months after GH cessation but started to decrease in the 18 months thereafter in males (P , 0.001) and between 2 and 5 years after GH cessation in females (P , 0.001). At 5 years after GH cessation, estimated mean (SE) BMAD LS SDS was 20.38 (0.1) in males (P , 0.001 compared with BMAD LS at GH cessation and P = 0.02 compared with 0 SDS) and 20.55 (0.1) in females (P , 0.001 compared with BMAD LS at GH cessation and 0 SDS).
To compare the individual BMD TB and BMAD LS of the SGA-GH patients to the healthy population, BMD TB and BMAD LS data points at GH cessation and 2 and 5 years thereafter were plotted against the reference curve of the healthy Dutch population (Fig. 2) . At GH cessation, 5.2% of the study population (males and females) had a BMD TB #22 SDS, which was a higher proportion than the expected 2.3% in the reference population (P = 0.019). At 5 years after GH cessation, only 1.3% of the study group had a BMD TB #22 SDS, which was similar to the expected proportion in the reference population (P = 0.48). At GH cessation, 3.5% had a BMAD LS #22 SDS (P = 0.21 compared with 2.3%). Also at 5 years after GH cessation, the proportion of patients with a BMAD LS #22 SDS was not significantly different from the expected 2.3% (P = 0.66).
Factors influencing the change in BMD TB and BMAD LS during the 5 years after GH cessation From GH cessation until 5 years thereafter, there was a decrease in LBM of 0.39 SDS and an increase in FM% of 0.56 SDS. We analyzed whether there was a correlation between these changes in body composition and the deterioration in BMD TB and BMAD LS SDS during the 5 years after GH cessation. There was neither a correlation between DLBM SDS and DBMD TB SDS (r = 0.17; P = 0.24) nor between DFM% SDS and DBMD TB SDS (r = 0.05; P = 0.75) and neither between DLBM SDS and DBMAD LS SDS (r = 0.17; P = 0.24) nor between DFM% SDS and BMAD LS (r = 0.18; P = 0.22).
From GH cessation until 5 years thereafter, serum IGF-1 levels decreased with 1.66 SDS. There was no correlation between DIGF-1 SDS and DBMD TB SDS (r = 0.40; P = 0.20). However, there was a trend toward a significant correlation between the decrease in IGF-1 SDS and the decrease in BMAD LS SDS (r = 0.57; P = 0.05).
BMD TB and BMAD LS at 5 years after GH cessation compared with SGA-S, SGA-CU, and AGA Table 2 shows the clinical characteristics of the SGA-GH young adults at 5 years after GH cessation compared with the SGA-S, SGA-CU, and AGA young adults. The percentage of males/females was similar in the four groups. Mean age was ;21 years in all groups. Due to the selection criteria, there were considerable differences in birth length SDS, birth weight SDS, height SDS, weight for age SDS, and body composition. The percentage of smokers and of girls who used oral contraceptives was similar in all groups.
We analyzed which variables contributed to BMD TB and BMAD LS in the total group consisting of SGA-GH, SGA-S, SGA-CU, and AGA at 21 years in a multiple regression analysis (Table 3) . In the first model with BMD TB as dependent variable, we included the variables sex, age, birth weight SDS, height SDS, LBM SDS (corrected for height and sex), and FM% SDS (corrected for age and sex). Male sex, height SDS, LBM SDS, and FM% SDS were all positively associated with BMD TB (P , 0.001 for sex, height, and LBM and P = 0.01 for FM%). Age and birth weight SDS were not associated with BMD TB . This model accounted for 38% of the variance in BMD TB . In the second model, we evaluated the effect of oral contraceptive use in girls, which was not a significant predictor of BMD TB (P = 0.27). In model 3, we included the subjects who were GH-treated during childhood as a dummy variable, showing that GH treatment was not a significant predictor of BMD TB at 5 years after GH cessation (P = 0.63).
The same variables were then included in the model with BMAD LS as dependent variable. Male sex was negatively associated with BMAD LS (P , 0.001). Height SDS was not significantly associated with BMAD LS , which was expected because BMAD LS is already corrected for bone size. LBM SDS and FM% SDS were positively associated with BMAD LS (P = 0.04 and P = 0.001, respectively). This model accounted for 18% of the variance in BMAD LS . In the second model, we evaluated the effect of oral contraceptive use in girls. This model showed that oral contraceptive use did not influence BMAD LS (P = 0.28). Finally, the dummy GH treatment was included in the model, showing that this was not a predictor of BMAD LS (P = 0.14). Figure 3 shows the comparisons of BMD TB and BMAD LS between the SGA-GH young adults at 5 years after GH cessation and the SGA-S, SGA-CU, and AGA young adults. Adjustments were made based on the noteworthy predictors in the multiple regression analysis. BMD TB in SGA-GH, adjusted for sex, height SDS, LBM SDS, and FM% SDS, was not different from BMD TB in SGA-S and SGA-CU (P = 0.22 and P = 0.76, respectively). There was a trend toward a lower BMD TB in SGA-GH than in AGA (P = 0.09). SGA-S and SGA-CU had a similar BMD TB , but both lower than AGA (P = 0.03). BMAD LS SDS, adjusted for sex, LBM SDS, and FM% SDS, was similar in SGA-GH and SGA-S, SGA-CU, and AGA (P = 0.63, P = 0.72, and P = 0.26, respectively).
Discussion
This study presents 5-year longitudinal data on BMD TB and BMAD LS after cessation of GH treatment in young adults born SGA. We show that cessation of GH treatment is accompanied with a trend toward a decline of BMD TB in males and a gradual decline of BMAD LS in males and females. However, at 5 years after cessation of treatment, previously GH-treated SGA young adults had a similar BMD TB and BMAD LS as young adults who remained untreated and as controls born AGA with a normal stature.
To our knowledge, this is the first study describing BMD TB and BMAD LS after cessation of GH treatment in a large group of young adults born SGA. Until now, there were limited data available. Our research group reported on BMD TB and BMAD LS in children born SGA during GH treatment (15, 16) . These studies were performed during 3 and 6 years, respectively, of treatment and reported a BMD TB SDS of 20.9 and a BMAD LS SDS of 20.6 at onset of treatment. Although we found that BMD TB was lower than average at cessation of GH treatment, both BMD TB and BMAD LS were higher than the baseline BMDs reported in previous studies. The same studies showed that during the first years of GH treatment, there was an increase of BMD TB and BMAD LS , which were maintained at the same level up to 6 years after the start of treatment. We can now conclude that these positive effects are maintained until AH attainment. During the 5 years after cessation of GH treatment, there was a gradual decline of BMAD LS and a trend toward a decline of BMD TB in males, probably due to the loss of pharmacological effects of GH treatment. The correlation between the decline in IGF-1 SDS levels and the deterioration in BMAD LS in the 5 years after GH cessation provides support for this explanation. In contrast to other metabolic changes after GH cessation (29) , the decrease in BMD TB and BMAD LS did not commence directly after cessation. In males, there was even an increase of BMD TB in the first 6 months after GH cessation. It could be that GH treatment has relatively longer-lasting effects on bone metabolism than on body mass and fat mass and that, therefore, there is not an immediate effect of GH cessation on BMD. Despite the deteriorations in the years after GH cessation, average BMD TB and BMAD LS at 5 years after GH cessation were above 21 SDS, and only a small percentage of all subjects had a BMD TB or BMAD LS below 22 SDS, which is reassuring. Most of the skeletal mass in the total body and lumbar spine is attained in the first years of the third decade (28, 30, 31) . This attained peak bone mass is an important determinant of osteoporosis in later life (8) . The higher BMD TB and BMAD LS at young adult age, the lower the risk of osteoporosis in later life. Thus, although BMD TB and BMAD LS in formerly GH-treated subjects were within the normal range, it is unfortunate that the beneficial effects of GH treatment disappear after cessation of treatment. Future studies should aim at investigating how BMD TB and BMAD LS progress when GH-treated subjects born SGA get older and what the long-term clinical implications will be.
Our multiple regression analysis could explain a relatively large part of the total variance in BMD TB and BMAD LS . Sex, height, LBM, and FM% were significant determinants of BMD TB and sex, LBM, and FM% of BMAD LS . The combination of LBM and FM% can also be seen as a measure of physical fitness, which is an important determinant of BMD TB and BMAD LS (32, 33) . Although GH-treated subjects had BMD TB and BMAD LS below average at 5 years after GH cessation, this did not significantly influence BMD TB and BMAD LS of the total group at the age of 21 years. We found no effect of oral contraceptive use in girls on BMD TB and BMAD LS , although the small number of girls who did not use oral contraceptives makes it difficult to draw definite conclusions. Another factor influencing BMD TB and BMAD LS in adolescence is pubertal stage, but because all participants were postpubertal in our cohort, this was already considered. Although the most important determinants of BMD TB and BMAD LS in a healthy young population were assessed in this study, there are of course other determining factors, such as calcium and vitamin D status. Unfortunately, there were no data on these factors available.
At 5 years after cessation of GH treatment, we additionally compared the data of the GH-treated subjects to age-matched clinically relevant subgroups of young adults born SGA with persistent short stature who were never treated with GH, young adults born SGA who showed spontaneous catch-up growth, and AGA-born controls with a normal stature. After correction for the noteworthy determinants of BMD TB and BMAD LS , we found no differences between the GH-treated and untreated young adults born SGA who remained short. 
